iPSC-based human organoid platforms for preclinical drug development

InnoCell is a biotechnology company specializing in the development of advanced three-dimensional human tissue models derived from induced pluripotent stem cells (iPSCs). We design and produce reproducible, scalable spheroids and organoid-like systems, including cardiac and neural models, to support preclinical drug development, toxicology, functional testing, and disease modeling.

Our platforms are built to improve human relevance and predictivity compared to conventional 2D cultures and animal models. We work with both healthy and disease-specific iPSC lines and can generate custom iPSC lines from donor material when required, enabling personalized and genetically defined in vitro systems. Our technologies are compatible with a wide range of readouts, including functional assays, biomarker analysis, and compound screening workflows.

Within a Horizon Europe consortium, InnoCell would contribute as a technology and model development partner, providing human iPSC-based 3D tissue systems for efficacy, safety, and mechanism-of-action studies. We are particularly interested in collaborations focusing on drug discovery, advanced preclinical validation, replacement or reduction of animal testing, and translational disease models.

We are seeking collaboration with consortium coordinators or partners developing therapeutic, diagnostic, or platform-focused proposals, where robust and human-relevant in vitro models are required. InnoCell can support both early-stage research and later-stage validation tasks, and is open to joint work package leadership in areas related to in vitro modeling, assay development, and translational testing.